NABIHEAL administrador 09/01/2023




Enero 2023 – diciembre 2026

Grant Agreement: 101092269


This project received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101092269.

Complex wounds impact the quality of life of more than 2% of total population in developed countries being a global health problem with significantly impacts on health care economy. Complex wounds, including chronic wounds or major burns, are highly susceptible to microbial infection and biofilm formation, difficult to treat. Silver is a metal widely used in antimicrobial products to treat wound infections.

However, silver-based products are expensive, and show several drawbacks due to costs, and environmental and safety concerns. NABIHEAL project will develop, from PoC (TRL3) to preclinical regulatory (TRL5), multifunctional biomaterials to solve some of the unmet medical needs in wound management, obtaining affordable treatments of wound infections or prevention of complications during all phases of wound healing. At short and medium term, NABIHEAL will end up with at least two innovative multifunctional wound healing biomaterials, using affordable EU-based manufacturing technologies. At long term, NABIHEAL could become a game-change alternative to silver in wound healing dressings. 

A consortium composed by 5 SME and 9 academic institutions, with expertise in wound healing product development, evaluation and commercialization, nanotechnology, safety, and regulatory will join forces to address this ambitious objective.

Histocell will contribute to NABIHEAL with its expertise on biomaterial development based on its proprietary technology REOXCARE as well as with its deep knowledge of wound healing treatment, medical devices manufacturing and understanding of the wound market. 

Press release

Project website: